Get started
BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BCRX chart


Full chart

BCRX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.57 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.61 USD
Net income (FY)
‪−226.54 M‬ USD
Revenue (FY)
‪331.41 M‬ USD
Shares float
‪196.10 M‬
Beta (1Y)
0.88

Employees


Employees (FY)
536
Change (1Y)
+5 +0.94%
Revenue / Employee (1Y)
‪618.31 K‬ USD
Net income / Employee (1Y)
‪−422.65 K‬ USD

About BioCryst Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Jon P. Stonehouse
Website
biocryst.com
Headquarters
Durham
Founded
1986
FIGI
BBG000BLYWX6
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

BCRX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of BCRX is 7.60 USD — it has increased by 1.47% in the past 24 hours. Watch BioCryst Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BioCryst Pharmaceuticals, Inc. stocks are traded under the ticker BCRX.
BCRX stock has risen by 1.33% compared to the previous week, the month change is a −4.04% fall, over the last year BioCryst Pharmaceuticals, Inc. has showed a 47.86% increase.
We've gathered analysts' opinions on BioCryst Pharmaceuticals, Inc. future price: according to them, BCRX price has a max estimate of 30.00 USD and a min estimate of 8.00 USD. Watch BCRX chart and read a more detailed BioCryst Pharmaceuticals, Inc. stock forecast: see what analysts think of BioCryst Pharmaceuticals, Inc. and suggest that you do with its stocks.
BCRX reached its all-time high on Mar 9, 2000 with the price of 37.25 USD, and its all-time low was 0.60 USD and was reached on Jun 26, 2002. View more price dynamics on BCRX chart.
See other stocks reaching their highest and lowest prices.
BCRX stock is 3.23% volatile and has beta coefficient of 0.88. Track BioCryst Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is BioCryst Pharmaceuticals, Inc. there?
Today BioCryst Pharmaceuticals, Inc. has the market capitalization of ‪1.57 B‬, it has increased by 6.54% over the last week.
Yes, you can track BioCryst Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
BioCryst Pharmaceuticals, Inc. is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
BCRX earnings for the last quarter are −0.07 USD per share, whereas the estimation was −0.07 USD resulting in a −1.61% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about BioCryst Pharmaceuticals, Inc. earnings.
BioCryst Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪117.08 M‬ USD, despite the estimated figure of ‪113.99 M‬ USD. In the next quarter, revenue is expected to reach ‪127.17 M‬ USD.
BCRX net income for the last quarter is ‪−14.03 M‬ USD, while the quarter before that showed ‪−12.67 M‬ USD of net income which accounts for −10.72% change. Track more BioCryst Pharmaceuticals, Inc. financial stats to get the full picture.
No, BCRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 536.00 employees. See our rating of the largest employees — is BioCryst Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioCryst Pharmaceuticals, Inc. EBITDA is ‪−39.34 M‬ USD, and current EBITDA margin is −30.79%. See more stats in BioCryst Pharmaceuticals, Inc. financial statements.
Like other stocks, BCRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioCryst Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioCryst Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioCryst Pharmaceuticals, Inc. stock shows the neutral signal. See more of BioCryst Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.